The effects of rosiglitazone on myocardial triglyceride content in patients with type 2 diabetes: A randomised, placebo-controlled trial

Jonathan McGavock, Lidia S. Szczepaniak, Colby R. Ayers, Shuaib M Abdullah, Raphael See, M. Odette Gore, Mark H Drazner, James A de Lemos, Darren K McGuire

Research output: Contribution to journalArticle

15 Scopus citations

Abstract

This was a nested sub-study of a randomised placebo-controlled trial of the effect of 6 months of treatment with rosiglitazone added to existing therapy on myocardial triglyceride (mTG) content in patients with type 2 diabetes (T2D) and prevalent cardiovascular disease (CVD) or at least one additional risk factor. The primary endpoint, mTG content, was measured with cardiac 1H-magnetic resonance spectroscopy. Of the 99 randomised participants selected for the imaging sub-study, 49 (48%) had complete and interpretable spectroscopy data (age = 58 years, duration of T2D = 9.5 years; 57% women and 69% non-white). There was no significant change in mTG in either group (?0.1 ± 0.6% and ?0.05 ± 0.8% respectively) and the changes in mTG were not associated with changes in left ventricular structure or function. Compared with placebo, treatment with rosiglitazone for 6 months had no discernible effect on mTG or left ventricular function in this population with long-standing diabetes and CVD.

Original languageEnglish (US)
Pages (from-to)131-137
Number of pages7
JournalDiabetes and Vascular Disease Research
Volume9
Issue number2
DOIs
StatePublished - Apr 1 2012

Keywords

  • Lipotoxicity
  • MRI
  • Steatosis
  • Thiazolidinedione

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'The effects of rosiglitazone on myocardial triglyceride content in patients with type 2 diabetes: A randomised, placebo-controlled trial'. Together they form a unique fingerprint.

  • Cite this